We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+9.75%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.94B
AUM Growth
+$582M
Cap. Flow
+$429M
Cap. Flow %
10.9%
Top 10 Hldgs %
57.23%
Holding
59
New
11
Increased
8
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$126M
2
IPSC icon
Century Therapeutics
IPSC
+$81.4M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$69.6M
4
AMRS
Amyris Inc.
AMRS
+$44.7M
5
ME
23andMe Holding Co
ME
+$28.5M

Top Sells

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$22.8M
2
ADVM
Adverum Biotechnologies
ADVM
+$21.8M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$16.7M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$11.7M
5
DYN icon
Dyne Therapeutics
DYN
+$9.47M

Sector Composition

Rank Sector Weight
1 Healthcare 88.3%
2 Materials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
26
DELISTED
Generation Bio
GBIO
$43.3M 1.1%
161,121
– –
CRSP icon
27
CRISPR Therapeutics
CRSP
$4.86B
$43.1M 1.09%
266,430
– –
ALEC icon
28
Alector
ALEC
$168M
$34.4M 0.87%
1,650,000
– –
ZLAB icon
29
Zai Lab
ZLAB
$2.06B
$33.6M 0.85%
190,000
– –
DNTH icon
30
Dianthus Therapeutics
DNTH
$5.72B
$32.7M 0.83%
209,127
– –
ME
31
DELISTED
23andMe Holding Co
ME
$32M 0.81%
+137,073
New +$28.5M
ALLO icon
32
Allogene Therapeutics
ALLO
$632M
$31.9M 0.81%
1,225,000
-75,000
-6% -$2.14M
FDMT icon
33
4D Molecular Therapeutics
FDMT
$523M
$26.9M 0.68%
1,115,555
+120,201
+12% +$3.68M
NEO icon
34
NeoGenomics
NEO
$2.04B
$22.1M 0.56%
+488,889
New +$21.7M
GLUE icon
35
Monte Rosa Therapeutics
GLUE
$1.31B
$21.8M 0.55%
+960,883
New +$19.6M
SNDX icon
36
Syndax Pharmaceuticals
SNDX
$1.69B
$20.6M 0.52%
1,200,000
+200,000
+20% +$3.66M
RXRX icon
37
Recursion Pharmaceuticals
RXRX
$1.68B
$20M 0.51%
+548,156
New +$16.2M
MASS icon
38
908 Devices
MASS
$342M
$15.8M 0.4%
406,502
– –
ORTX
39
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$14.1M 0.36%
321,543
– –
KRON
40
DELISTED
Kronos Bio
KRON
$14M 0.35%
583,436
– –
FULC icon
41
Fulcrum Therapeutics
FULC
$280M
$12.1M 0.31%
1,154,476
-86,700
-7% -$877K
ORIC icon
42
Oric Pharmaceuticals
ORIC
$1.09B
$10.6M 0.27%
601,515
– –
DBTX
43
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$10.1M 0.26%
1,171,421
+25,000
+2% +$221K
CLOV icon
44
Clover Health Investments
CLOV
$2.26B
$9.68M 0.25%
726,511
– –
CELL
45
DELISTED
PhenomeX Inc. Common Stock
CELL
$8.96M 0.23%
200,000
– –
TKNO icon
46
Alpha Teknova
TKNO
$278M
$7.12M 0.18%
+300,000
New +$7.59M
SGMO
47
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.58M 0.17%
550,000
– –
TPTX
48
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$5.85M 0.15%
75,000
– –
NAUT icon
49
Nautilus Biotechnolgy
NAUT
$127M
$5.05M 0.13%
+500,000
New +$5.42M
SEER icon
50
Seer Inc
SEER
$123M
$4.92M 0.12%
150,000
– –
1
2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Casdin Capital held 59 positions worth $3.94B, up 17% from $3.36B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Casdin Capital deployed $429M of net new capital in Q2 2021, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Verve Therapeutics: 3,038,167 shares worth $183M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $11.7M trimmed.

  • Casdin Capital's largest Q2 2021 buy was Verve Therapeutics: 3,038,167 shares worth $183M.
  • Casdin Capital added most to Sarepta Therapeutics in Q2 2021, an estimated $25.4M increase.
  • Casdin Capital's biggest Q2 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $11.7M.
  • Casdin Capital fully exited Burning Rock Biotech in Q2 2021, selling an estimated $22.8M.
  • Casdin Capital's ten largest holdings make up 57% of its $3.94B portfolio in Q2 2021.
  • Casdin Capital opened 11 new positions and closed 5 in Q2 2021.
  • Casdin Capital's portfolio value rose 17% quarter-over-quarter to $3.94B.

Based on Casdin Capital's 13F filing for Q2 2021, filed 16 Aug 2021.